Validation of the OHI Index for Hematologic Malignancies

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to validate the Optimized HLH Inflammatory (OHI) index in patients with hematologic malignancies who may develop hemophagocytic lymphohistiocytosis (HLH). It will enroll patients with new or transformed hematologic malignancies and follow them to assess their survival and prognosis over one year. The OHI index is based on specific biomarkers, including elevated levels of soluble CD25 and ferritin, which may help in diagnosing and predicting outcomes for patients with this serious condition.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with hematologic malignancies
* At least 18 years old

Exclusion Criteria:

* Prior recent treatment (chemotherapy/ other cytoreductive therapies in the last month)

Where it's running

• Meir Medical Center
  Kfar Saba, Israel Recruiting
• Rabin Medical Center
  Petah Tikva, Israel Recruiting

Study contacts

• Principal investigator: Adi Zoref-Lorenz — Meir Medical Center
• Study coordinator: Adi Zoref Lorenz, MD
• Email: adi.zoref.lorenz@cchmc.org
• Phone: 513 6525610

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• National Egyptian HLH Registry for pediatric patients

  A national HLH registry is being created in Egypt to collect information about pediatric HLH patients to improve understanding and care.

  Recruiting Ain Shams University · Cairo and 1 other locations · NCT07800234

• High-dose vs standard-dose flu vaccine in adults with blood cancers on B-cell-depleting therapy

  This study tests whether a high-dose flu shot evokes a stronger immune response than a standard-dose shot in adults with hematologic cancers who recently had B-cell-depleting therapy.

  Recruiting Phase 2 Asan Medical Center · Seoul · NCT07926217

• Anti-CD25 antibody to prevent acute GVHD after haploidentical stem cell transplant

  This study tests whether an anti-CD25 antibody can better prevent acute graft-versus-host disease after haploidentical hematopoietic stem cell transplantation compared with the usual methotrexate-based approach.

  Recruiting Phase 3 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07689630

• CD45RA-depleted donor cells to help fight stubborn viral infections after haploidentical transplant

  This trial tests whether giving patients specially prepared donor immune cells (CD45RA-depleted DLI) can help clear viral infections that linger after a stem cell transplant and who have not fully recovered their immunity.

  Recruiting Phase 1/2 Ruijin Hospital · Shanghai, SH · NCT07662369

• KK2430 in people with hematologic cancers

  This study tests KK2430 in adults with blood-related cancers to see if it is safe and how it behaves in the body, with the goal of understanding its potential to help in treatment.

  Recruiting Phase 1/2 Kyowa Kirin Co., Ltd. · Greenville, South Carolina · NCT07629726

• Identifying biomarkers for CAR-T cell therapy in cancer patients

  This study looks at real-world CAR-T therapy in adults with blood cancers to see which biomarkers predict who responds or relapses.

  Recruiting University Hospital, Lille · Lille and 1 other locations · NCT07609485

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.